Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q3 FY26 Earnings Presentation
24 slides from Morepen Laboratories's earnings presentation, Feb 10, 2026
Slide 1: Cover letter to stock exchanges: Investor Presentation Q3 FY26
Date: 10/02/2026 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288 Subject: Investor Presentation - Q3’ FY26 Dear Sir/ Madam, Please
Slide 2: Q3'FY26 Investor Presentation
Q3'FY26 investor presentation MOREPEN LABORATORIES LIMITED
Slide 3: Safe Harbour
SAFE HARBOUR This investor presentation has been prepared for general information purposes in respect of Morepen Laboratories Limited (“Company”) together with its subsidiary, as applicable (together, with the Company, the “Group”) only, without regard to any specific objectives, suitability, financ
Slide 4: Executive Summary
EXECUTIVE sUmMMaARY
Slide 5: Executive Summary: Business Segments
Q3'FY26 1 Executive Summary Business Segments: standAlone Pharma Business Medical Devices API+Rx Point of Care 62% 38% Share of Pharma Share of Medical Business Devices
Slide 6: Executive Summary: Gross Revenue Standalone
Q3'FY26 1 Executive Summary Gross revenue: Standalone Rs. in Crores 9M Revenue quarterly Revenue 1400 1185 1231 1200 500 462 4% 408 13% 1000 400 800 300 600 200 400 200 100 0 0 9M FY25 9M FY26 Q3 FY25 Q3 FY26
Slide 7: Gross Revenue: Continent-wise Share
Q3'FY26 1 Gross revenue Continent-wise share: USA USA 6.2% S. America 3% 2.2% Europe 17.1% Europe 17.3% 9M Q3 Asia FY26 FY26 13.2% India 61.6% Asia India 12.7% 64.1% S. America 2.7%
Slide 8: Pharma Business
2 Pharma Business
Slide 9: Pharma Business: Total Pharma Revenue
Q3'FY26 2 Pharma Business Total Pharma revenue : (API + formulations) Rs. in Crores 9m Revenue quarterly Revenue 791 767 800 3% 300 285 285 600 250 400 200 150 200 100 50 0 0 9M FY25 9M FY26 Q3 FY25 Q3 FY26
Slide 10: Pharma Business/API: Product-wise Breakup
Q3'FY26 2 pHarma Business/API Product-wise breakup: Sita Others 2.8% Monte 7.6% 16.2% Lina 2.8% Dapa 4.3% Rosu 11.8% 9M FY26 Lorata +Des 21.6% Fexo API revenue split 6.9% Atorva 26%
Slide 11: Pharma Business/API: Continent-wise Sales Share
Q3'FY26 2 pHarma Business/API Continent-wise API SAles share: S. America USA 4% 11.4% India 30.8% 9M FY26 Europe 31.6% Asia 22.2%
Slide 12: Pharma Business/API: API Revenue
Q3'FY26 2 Pharma Business/API Rs. in Crores API revenue : 9M Revenue quarterly Revenue 800 706 300 673 5% 251 249 1% 600 250 200 400 150 100 200 50 0 0 9M FY25 9M FY26 Q3 FY25 Q3 FY26
Slide 13: Pharma Business/Finished Dosages: Formulation
Q3'FY26 2 pHarma Business/Finished Dosages Formulation Rs. in Crores 9M Revenue quarterly Revenue 100 93 40 82 14% 35 80 32 11% 30 60 20 40 20 10 0 0 9M FY25 9M FY26 Q3 FY25 Q3 FY26
Slide 14: Medical Devices
3 Medical devices
Slide 15: Medical Devices: Top Selling Products
Q3'FY26 3 Medical Devices Top selling Products: Blood Glucose meters BP Monitors Nebulisers Thermometers Ortho supports Pregnancy Kits
Slide 16: Medical Devices: Total Revenue
Q3'FY26 3 Medical Devices Total revenue : Rs. in Crores 9M Revenue quarterly Revenue 500 464 200 177 394 18% 44% 400 150 123 300 100 200 100 50 0 0 9M FY25 9M FY26 Q3 FY25 Q3 FY26
Slide 17: Glucometer Leadership
Q3'FY26 3 Medical Devices glucometer Leadeship: 16.85 mn 2.33 bn gluco meters sold Gluco Strips sold Happy customer base Individual tests strips Cumulative YTD numbers
Slide 18: Medical Devices: Gluco Meter Revenue
Q3'FY26 3 Medical Devices Gluco meter revenue Rs. in Crores 9M Revenue quarterly Revenue 140 134 400 361 40% 18% 120 307 300 100 96 80 200 60 40 100 20 0 0 9M FY25 9M FY26 Q3 FY25 Q3 FY26
Slide 19: Medical Devices: BP Monitor Revenue
Q3'FY26 3 Medical Devices BP Monitor revenue : Rs. in Crores 9M Revenue quarterly Revenue 80 78 35 73 31 6% 30 27% 60 25 24 20 40 15 10 20 5 0 0 9M FY25 9M FY26 Q3 FY25 Q3 FY26
Slide 20: Medical Devices: Product-wise Breakup
Q3'FY26 3 Medical Devices Product-wise breakup: Others 6.6% BP Monitors 17.4% PRODUCT share Medical Devices Q3 FY26 Glucose Monitors 76%
Slide 21: Financial Overview
Q3'FY26 4 financial Overview
Slide 22: Financial Overview: Quarterly Performance Standalone
Q3'FY26 4 Financial Overview Quarterly Performance: STANDALONE Rs. in Crores Gross Revenue EBITDA PAT : 500 462 50 46 25 23 23% 400 374 40 41% 77% 33 20 300 30 15 13 200 20 10 100 10 5 0 0 0 Q2 FY26 Q3 FY26 Q2 FY26 Q3 FY26 Q2 FY26 Q3 FY26 *Net of exceptional income of Rs. 1.10 crores.
Slide 23: Financial Overview: Quarterly Performance Consolidated
Q3'FY26 4 Financial Overview Quarterly Performance: consolidated Rs. in Crores Gross Revenue EBITDA PAT : 500 488 50 50 30 28 416 17% 42% 400 40 35 25 83% 300 20 30 15 * 15 200 20 10 100 10 5 0 0 0 Q2 FY26 Q3 FY26 Q2 FY26 Q3 FY26 Q2 FY26 Q3 FY26 *Net of exceptional income of Rs. 25.83 crores.
Slide 24: Thank you
NOREEN Indilk YUU www.morepen.com